Revolutionary Weight Loss Drug Eliminates Need for Surgery

A next-generation GLP-1 receptor agonist developed by Eli Lilly has shown unprecedented results in clinical trials, with patients losing an average of 35% of their body weight over 18 months???results comparable to bariatric surgery but without the risks.

The Drug

The medication, called retatrutide, works by targeting three receptors simultaneously (GLP-1, GIP, and glucagon). Unlike current options like Ozempic and Mounjaro, it requires only monthly injections and shows significantly fewer side effects.